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Introduction
Macroautophagy, hereafter referred to as autophagy, is an essen-
tial biological process for degrading cellular materials via the 
lysosome (1). Disruption of autophagy in various organs results in 
pathological changes that in some cases can be ascribed to a fail-
ure to degrade harmful cellular constituents (2), but in other cases 
are not fully understood mechanistically. Autophagy deficiency 
in the liver leads to hepatomegaly, cellular injury, inflammation, 
fibrosis, expansion of hepatic progenitor cells (HPCs) or ductular 
cells (DCs), and tumor development, the underlying mechanisms 
of which are still unclear. These pathological changes mirror those 
observed in other liver diseases with different etiologies. Thus, 
while the insulting events are different, the subsequent patho-
logical changes may share common pathways. A commonly held 
notion is that cell death can lead to inflammation, or vice versa, 
and that this vicious cycle in a chronic disease course results in 
significant tissue injury, which is accompanied by a certain degree 
of tissue repair and fibrosis. In the cycle of destruction and regen-
eration, genomic instability can be induced, which can ultimately 
lead to cancer development (3, 4). However, the molecular signal-
ing events that individually regulate and/or globally connect these 
processes are not fully understood.
High-mobility group box 1 (HMGB1) is a damage/danger- 
associated molecular pattern (DAMP) molecule (5, 6). HMGB1 is 
expressed in virtually all nucleated eukaryotic cells. It is mainly 
located in the nucleus but can also be found in the cytosol and the 
extracellular space. In the nucleus, fully reduced HMGB1 binds to 
DNA and facilitates DNA-protein interaction, gene transcription, 
and DNA replication and repair. Its extracellular function as a 
DAMP molecule is best studied in association with sepsis, tissue 
injury, inflammation, and fibrosis (5–10). The release of HMGB1 
can be passive, from dead cells, but can also be active, from acti-
vated macrophages (11–13). Extracellular HMGB1 can recruit 
immune cells, induce cytokines and chemokines, and promote 
inflammation, angiogenesis, and tissue repair (5, 6, 14).
Hepatic HMGB1 can participate in inflammation, fibrosis, and 
injury caused by hepatitis C virus (HCV) or CCl4 (7), ischemia/
reperfusion (15), acetaminophen (10), or ethanol (16). It was there-
fore reasonable to hypothesize that HMGB1 could participate in 
the liver pathology induced by autophagy deficiency. Indeed, 
in this study, we found that HMGB1 in hepatocytes translocated 
from the nucleus to the extracellular space in response to autopha-
gy deficiency in the liver. We show that the molecular pathway that 
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LC3 (LC3-II), the accumulation of p62 (also known as SQSTM1), 
an adaptor molecule subjected to autophagy degradation, and the 
activation of NRF2, leading to an increased expression of the NRF2 
target genes Nqo1 and Gst in a time-dependent manner (Figure 1A). 
We found that the kinetics of HMGB1 protein level decline were 
similar (Figure 1A), with no changes in mRNA levels (Supplemen-
tal Figure 1A; supplemental material available online with this arti-
cle; https://doi.org/10.1172/JCI91814DS1). Other organs in Atg7ΔHep 
mice did not show HMGB1 reduction or translocation (Supplemen-
tal Figure 1, B and C). The loss or translocation of HMGB1 occurred 
in hepatocytes, but not in the nonparenchymal cells in the liver 
(Figure 1B), which was confirmed using isolated hepatocytes and 
nonhepatocytes (Supplemental Figure 1D).
connects autophagy deficiency to the active release of HMGB1 is 
mediated via NRF2 and inflammasomes. Surprisingly, hepato-
cyte-derived HMGB1 did not critically affect sterile inflammation 
or fibrosis, but promoted repair-associated DC/HPC expansion 
and tumor development in autophagy-deficient livers. These find-
ings indicate that hepatocyte-derived HMGB1 can play important 
roles in liver pathology under autophagy-deficient conditions.
Results
Autophagy-deficient hepatocytes release HMGB1. In our investigation 
of the mechanism of liver injury under autophagy deficiency, we 
examined HMGB1 levels in the liver. Deletion of a key autophagy 
gene, Atg7, in the liver (Atg7ΔHep) caused loss of the lipidated form of 
Figure 1. Hepatic autophagy deficiency causes HMGB1 release from hepatocytes. (A) Immunoblot analysis of hepatic lysates from Atg7fl/fl and Atg7ΔHep 
(Atg7–/–) mice at the indicated ages. (B) Liver sections from 9-week-old Atg7fl/fl mice and Atg7ΔHep mice at different ages were immunostained for HMGB1. (C) 
Percentage of hepatocytes with nuclear or cytosolic HMGB1 (n = 3 mice/group). (D) Serum HMGB1 levels in 6-week-old mice (n = 4–7 mice/group). (E and F) Liv-
er sections or lysates from 9-week-old Atg5fl/fl and Atg5ΔHep (Atg5–/–) mice were subjected to immunostaining (E) or immunoblot assay (F) for HMGB1. Arrows 
in E indicate hepatocytes without nuclear HMGB1. (G) HMGB1 species in the serum were analyzed by mass spectrometry. Diagrams shown are from represen-
tative experiments. Peaks representing different forms of HMGB1 are indicated with red arrows. Intensity scales are relative to each group. Scale bars: 10 μm. 
Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA with Duncan’s post hoc analysis (C) and 2-sided Student’s t test (D).
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renal proximal tubules and a corresponding elevation of serum 
HMGB1 in this strain of mice (Supplemental Figure 1, G and H). 
These results suggest that an alteration of HMGB1 cellular loca-
tion could be a common phenomenon in autophagy deficiency.
Mass spectrum analysis indicated that the small amount 
of HMGB1 in the serum of floxed mice was mainly in the fully 
reduced form, but released HMGB1 was mainly in the disulfide 
form in the serum of Atg7ΔHep or Atg5ΔHep mice (Figure 1G). In addi-
tion, the acetylated form of HMGB1 was detected in Atg7ΔHep and 
Atg5ΔHep sera, but not in the sera of the floxed control mice, con-
sistent with the previous finding that acetylation of HMGB1 pro-
motes its nucleus-to-cytosol transport, a precondition for sub-
sequent release to the extracellular space (17). In contrast to the 
control, the disulfide form of serum HMGB1 was more dominant 
than the reduced form under the autophagy-deficient conditions, 
regardless of whether or not acetylation occurred, suggesting an 
HMGB1 signal was present in the hepatocyte nucleus of control 
Atg7-floxed (Atg7fl/fl) livers. In 3-week-old Atg7ΔHep mice, HMGB1 
was mainly found in the cytosol of the hepatocyte (Figure 1, B and 
C), indicating an enhanced nucleus-to-cytosol translocation. Over 
time, both nuclear and cytosolic HMGB1 were decreased in Atg7–/– 
hepatocytes, with the nadir occurring at 9 weeks of age. Concom-
itantly, we detected significantly elevated levels of HMGB1 in the 
Atg7ΔHep serum (Figure 1D), supporting the notion that HMGB1 loss 
in hepatocytes is due to its release. In older mice (12–16 weeks of 
age), approximately 20% of hepatocytes retained nuclear HMGB1 
(Figure 1, B and C), perhaps reflecting the steady production-re-
lease dynamics of intracellular HMGB1.
We confirmed the loss of HMGB1 in hepatocyte nuclei in 2 
other strains of hepatocyte-specific, autophagy-deficient mice: 
Atg5ΔHep (Figure 1, D–F) and Vps34ΔHep (Supplemental Figure 1, E 
and F). We also detected HMGB1 release from Atg7-deficient 
Figure 2. HMGB1 promotes DR in autophagy-deficient livers. (A–F) Mice were analyzed for liver weight (LW) versus body weight 
(BW) (A), for levels of serum ALT (B), AST (C), and ALP (D), the number of Kupffer cells (E), and the fibrotic area (F) (n = 4–7 
mice/group). (G and H) Liver sections were subjected to H&E staining (original magnification, ×200) and immunostaining. DCs/
HPCs were quantified (n = 3 mice/group). Scale bars: 50 μm (CK19, A6, and EPCAM) and 10 μm (SOX9). Data represent the mean 
± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA with Duncan’s post hoc analysis.
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(Atg7ΔHep Hmgb1ΔHep) or were deficient in both Atg5 and Hmgb1 in 
hepatocytes (Atg5ΔHep Hmgb1ΔHep). Immunostaining for HMGB1 
confirmed the absence of HMGB1 in hepatocytes, but not in non-
hepatocytes in these mice (Supplemental Figure 2, A and B). We 
were consistently unable to detect HMGB1 in the sera of Atg7ΔHep 
Hmgb1ΔHep mice (Supplemental Figure 2C).
Codeletion of Hmgb1 in autophagy-deficient livers did not 
reduce NRF2 activation or p62 accumulation, but elevated 
hepatomegaly and hepatic injury (Figure 2, A–D, Supplemental 
Figure 3A, and Supplemental Figure 4, A and B). Inflammation 
in autophagy-deficient livers was evident by the expansion of 
increased oxidization environment in autophagy-deficient livers. 
The different forms of HMGB1 could trigger different types of cel-
lular response (6). As such, we would choose the disulfide form of 
recombinant HMGB1 in subsequent in vitro studies (see below).
Hepatocyte-derived HMGB1 is important for DR, but not for 
inflammation or fibrosis. Autophagy-deficient livers manifest mul-
tiple pathological changes, including hepatocyte hypertrophy, 
inflammation, fibrosis, DR, and tumor development (18–21). To 
determine whether HMGB1 released from autophagy-deficient 
hepatocytes played a role in the phenotypic changes, we gen erated 
mice that were deficient in both Atg7 and Hmgb1 in hepatocytes 
Figure 3. Pharmacological inhibition of HMGB1 release prevents DR. (A and B) Two-week-old mice were given EP i.p. (40 mg/kg) or the vehicle control 
twice a week for 2 (A) or 4 (B) weeks, and then analyzed 2 weeks later. Liver lysates and the nuclear fraction were examined by immunoblot assay. (C) 
Liver sections were stained as indicated. White arrows indicate nuclei that lost HMGB1 in Atg7–/– without EP treatment. (D and E) Liver sections were H&E 
stained (original magnification, ×200) or immunostained as indicated (D). The framed areas are enlarged in separate panels. SOX9+ and CK19+ cells were 
quantified (E) (n = 3 mice/group). Scale bars: 10 μm (C and SOX9 in D) and 50 μm (CK19 in D). Original magnification, ×200 (F4/80 in D). Data represent the 
mean ± SEM. **P < 0.01 and ***P < 0.001, by 1-way ANOVA with Duncan’s post hoc analysis.
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Atg7ΔHep or Atg5ΔHep mice and their littermates with deletion of 
Hmgb1. Fibrosis was clearly detected in autophagy-deficient liv-
ers by trichrome or Picrosirius red staining (Supplemental Figure 
3C and Supplemental Figure 4C). We also observed a notable 
F4/80+ macrophages, CD3+T cells, and CD45R+ B cells, but not 
MPO+ neutrophils (Figure 2E, Supplemental Figure 3B, and Sup-
plemental Figure 4C). We observed no obvious differences in the 
numbers of F4/80+ macrophages or other immune cells between 
Figure 4. RAGE is required for DR in autophagy-deficient livers. (A and B) LW/BW and serum ALT levels were determined for 9-week-old mice (n = 3–6 
mice/group). (C and D) Liver sections were stained for F4/80 or desmin (C, original magnification, ×200) or H&E (D, original magnification, ×200). Framed 
areas in D were enlarged and are shown on the right. (E) Quantification of CK19+, A6+, and SOX9+ cells (n = 3 mice/group). Images are shown in Supplemental 
Figure 8C. (F and G) Hepatic nonparenchymal cells were isolated from Atg7Hep-ERT2 mice 70–100 days after tamoxifen treatment and were further fractioned 
on a Nycodenz density gradient. Quantitative real-time PCR (qRT-PCR) was performed on the 4 fractions (F1–F4) and hepatocytes (Hep). F2 cells were 
immunostained with anti-CK19 and anti-RAGE. Data are representative of 2 experiments. (H) F2 (1.7 × 105 cells/well) and F1 (2 × 105 cells/well) cells and 
F3 and F4 cells (5 × 105 cells/well) were cultured overnight and treated as indicated for 2 hours. Disulfide HMGB1: 60 ng/ml; anti-RAGE antibody: 2 μg/ml. 
T-ERK1/2, total ERK1/2; p-ERK1/2, phosphorylated ERK1/2. Scale bars: 50 μm (C) and 10 μm (G). Data represent the mean ± SEM. **P < 0.01 and ***P < 
0.001, by 1-way ANOVA with Duncan’s post hoc analysis.
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increase in desmin+ stellate cells, as well as increases in α- 
hydroxyproline, the expression of fibrogenic genes (Col1a1 and 
Ctgf) and α–smooth muscle actin (α-SMA) (Supplemental Figure 
4, A and C–F), and increases in fibrotic area (Figure 2F). How-
ever, codeletion of Hmgb1 in autophagy-deficient livers did not 
alter these changes. These results suggest that hepatic HMGB1 
was dispensable for the development of inflammation and fibro-
sis in autophagy-deficient livers.
A prominent pathological change in the autophagy-deficient 
liver is the ductular reaction (DR), which, to our knowledge, has 
not been detailed in previous studies. We found that codeletion 
of Hmgb1 in Atg7ΔHep or Atg5ΔHep mice affected DR (Figure 2, G and 
H, and Supplemental Figure 4D). DR is the expansion of DCs, 
also known as HPCs or oval cells (22–24). Under H&E staining, 
these cells are small in size, with a high nucleus/cytoplasm ratio, 
and are distributed in a chain or clustered pattern (Figure 2G and 
Supplemental Figure 4D). Phenotypically, murine DCs/HPCs 
express mainly markers of biliary epithelial cells (22–24). Thus, 
we observed a significant increase in cells positive for CK19, A6, 
SOX9, or EPCAM in Atg7ΔHep and Atg5ΔHep livers (Figure 2, G and H, 
and Supplemental Figure 4D). DCs/HPCs were almost complete-
ly abolished in Atg7ΔHep Hmgb1ΔHep and in Atg5ΔHep Hmgb1ΔHep livers. 
These results indicate that HMGB1 was required for the expansion 
of DCs/HPCs in autophagy-deficient livers. We found that DR 
was still suppressed in 9-month-old Atg7ΔHep Hmgb1ΔHep mice (Sup-
plemental Figure 5), indicating the long-term dependence of DCs/
HPCs on HMGB1 for expansion, which could not be compensated 
by other mechanisms.
We also assessed whether DR also depended on HMGB1 in liv-
er injury caused by toxic diets. The 3,5-diethoxycarbonyl-1,4-dihy-
drocollidine–supplemented (DDC-supplemented) diet (25) and the 
choline-deficient, ethionine–supplemented (CDE-supplemented) 
diet (26) can cause liver injury with significant DR. Indeed, DDC 
and CDE diets both induced HMGB1 release from hepatocytes 
(Supplemental Figure 6, A–D, and Supplemental Figures 7, A and 
B). Furthermore, DR, as measured by the level of CK19+ or A6+ cells 
or by H&E staining (Supplemental Figures 6, E–I, and Supplemen-
tal Figure 7, C and D), was significantly suppressed in Hmgb1ΔHep 
livers, with no changes in liver injury (Supplemental Figures 6J). 
These results confirmed that HMGB1 was also required for the 
expansion of DCs/HPCs in response to a DDC or CDE diet.
HMGB1 acts extrinsically via its receptor for RAGE to promote 
DR. To determine whether HMGB1 promotes DR as an extrin-
sic mechanism, we treated 2-week-old Atg7ΔHep mice with ethyl 
pyruvate (EP) twice a week for 2 or 4 weeks (Figure 3, A and 
B). EP is a potent lipophilic aliphatic ester of pyruvic acid, and 
it has been shown to inhibit HMGB1 release in sepsis (27, 28). 
EP was well tolerated and did not change autophagy deficiency, 
as p62 accumulation, nuclear translocation of NRF2, and NRF2 
activation were retained (Figure 3A). Hepatic HMGB1 release 
in Atg7ΔHep mice was inhibited in mice that received EP for 2 or 4 
weeks (Figure 3, A–C). Consistently, EP treatment significantly 
inhibited DR in Atg7ΔHep livers and the expansion of DCs/HPCs 
(Figure 3, D and E). In contrast, F4/80 cell infiltration was not 
affected (Figure 3D). These results support the notion that 
hepatocyte-released HMGB1 could act extrinsically to promote 
the expansion of DCs, which was inhibited by EP via the sup-
pression of HMGB1 release.
HMGB1 acts through agonist receptors including the recep-
tor for advanced glycation end products (RAGE) and several 
TLRs (6). We detected a small increase in the expression of Rage 
mRNA in autophagy-deficient livers (Supplemental Figure 8A). 
Codeletion of Rage did not protect the autophagy-deficient mice 
from liver injury or hepatomegaly (Figure 4, A and B), nor did 
it seem to protect their livers against inflammation or stellate 
cell expansion (Figure 4C). In addition, Rage deletion alone or 
Rage codeletion in Atg7ΔHep mice did not affect HMGB1 release 
from hepatocytes (Supplemental Figure 8B). However, codele-
tion of Rage resulted in inhibition of DR (Figure 4D) and a sup-
pression of the expansion of A6+, CK19+, or SOX9+ DCs/HPCs 
(Figure 4E and Supplemental Figure 8C). Notably, Rage deletion 
also inhibited DDC diet–induced CK19+ cell expansion (Sup-
plemental Figure 6, E and F). These results thus indicated that 
hepatocyte-derived HMGB1 caused DC expansion extrinsically 
through RAGE-mediated signaling.
To further examine the role of RAGE in the process, we iso-
lated the putative DCs/HPCs using Nycodenz density gradient 
centrifugation (25). The fraction 2 (F2) cells isolated using this 
protocol had been characterized as the DCs/HPCs that contribute 
to DR (25). We isolated the F2 cells from the livers of Atg7Hep-ERT2 
mice 70–100 days after tamoxifen induction, when DR was well 
developed (see below). We found that these F2 cells were enriched 
for the expression of RAGE and CK19, but not for albumin, F4/80, 
or α-SMA (Figure 4F). Immunostaining confirmed the strong 
presence of both RAGE and CK19 in these cells (Figure 4G). When 
treated with recombinant disulfide HMGB1 proteins, F2 cells, but 
not other fractions of cells (F1, F3, F4), showed enhanced phos-
phorylation of ERK1/2, which was blocked by anti-RAGE antibody 
(Figure 4H), suggesting that these F2 cells had a RAGE-depen-
dent proliferative response to HMGB1. In addition, we examined 
the well-defined DC/HPC cell line BMOL (29), which expressed 
A6, CK19, and RAGE (Supplemental Figure 9A) and responded 
to recombinant disulfide HMGB1 with enhanced ERK1/2 phos-
phorylation in a dose- and time-dependent manner, which was 
blocked by the anti-RAGE antibody (Supplemental Figure 9, B–D). 
The enhanced effect of HMGB1 in the presence of serum was also 
suppressed by anti-RAGE in both F2 and BMOL cells (Figure 4H 
and Supplemental Figure 9D). Taken together, these data support 
Figure 5. HMGB1 and RAGE promote tumorigenesis in autophagy-defi-
cient livers. (A) Gross observation of tumors (arrows) from 9- to 17-month-
old mice. (B) Average number of tumors (by gross observation) in the livers 
of Atg7–/– and Atg7 Hmgb1–/– mice. (C) Average size distribution of the 
tumors observed in Atg7–/– (n = 12) and Atg7 Hmgb1 –/– (n = 16) livers, with 
all age groups combined. (D and E) Average number and size distribution 
of tumors (by gross observation) in livers from 9-month-old mice (n = 7–8 
mice/group). (F) qRT-PCR analysis of hepatic expression of Afp, Igf2, and 
Rex3 in 9-month-old mice (n = 3–6 mice/group). (G) Immunoblot analysis 
of hepatic lysates from mice of the indicated ages. (H) Hepatic mRNA 
levels of Hedgehog signaling components in mice (n = 3 mice/group). (I) 
GLI2 staining of hepatic sections from 9-week-old mice. Arrows indicate 
GLI2 staining in hepatocytes, and arrowheads indicate GLI2 staining in 
nonparenchymal cells. Scale bars: 1 cm (A) and 10 μm (I).Data represent 
the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA 
with Duncan’s post hoc analysis (D–F and H) and by 2-sided Student’s t 
test (B and C).
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been implicated in tumor development in the liver and other 
tissues (33, 34).
We therefore sought to determine whether there were any 
differences in tumor development between Atg7ΔHep and Atg7ΔHep 
Hmgb1ΔHep mice. Atg7fl/fl or Hmgb1ΔHep mice did not develop tumors 
within the 17-month observation period, but we observed a nota-
ble number of hepatic tumors in Atg7ΔHep mice starting at the age of 
9 months, a trend that increased steadily through 15 to 17 months 
(Figure 5, A–C). Gross examination revealed no tumors in the 
livers of Atg7ΔHep Hmgb1ΔHep mice at 9 months of age (Figure 5, A 
the role of HMGB1 in promoting the proliferation of RAGE+ DCs/
HPCs in a RAGE-dependent fashion.
HMGB1 and RAGE promote tumorigenesis in autophagy- 
deficient livers. The functional role of DR in liver disease is not 
very well understood. It has been postulated that DCs/HPCs 
may serve as a regenerating pool for hepatocytes and chol-
angiocytes during chronic liver injury (22–24). Beyond liver 
repair, DCs are also implicated in the cellular compartment 
susceptible to malignant transformation (30, 31), although 
direct evidence has not been found (32). HMGB1 has also 
Figure 6. HMGB1 release is an early event following loss of autophagy function. (A) Atg7Hep-ERT2 mice were given tamoxifen on days 1 and 2. Livers were 
removed at different time points (days 5–20) and analyzed by immunoblot assay. Mice in the day 0 group received the vehicle control. (B) Densitometric 
levels of ATG7, HMGB1, NQO1, and p62 were normalized to GAPDH levels and to the day 0 control group. (C) Liver sections from Atg7Hep-ERT2 mice at different 
time points after induction were stained for HMGB1. Arrows indicate HMGB1-negative nuclei in hepatocytes. Scale bars: 10 μm. (D) Serum HMGB1 levels 
were determined in Atg7Hep-ERT2 mice from day 0 to day 30 after tamoxifen treatment. Significance was compared with day 0 (n = 4 mice/group). Insert 
shows the negative correlation of serum HMGB1 level with that of hepatic HMGB1 (from B). (E) Liver/body weight ratio (LW/BW) and serum ALT level were 
determined after tamoxifen treatment (n = 3 mice/group). Only statistically significantly different data are labelled with the asterisk (compared with day 
0). (F) Liver sections from Atg7Hep-ERT2 mice at different time points after induction were H&E stained. Original magnification, ×400. (G and H) The number 
of hepatic CK19+ (G) and A6+ (H) cells was quantified in Atg7Hep-ERT2 mice at different time points after induction (n = 3 mice/group). See also the images in 
Supplemental Figure 12, E–F. (I) The number of hepatic CK19+ or SOX9+ cells was quantified in the indicated mice on days 0 and 50 after induction (n = 3 
mice/group). See also the images in Supplemental Figure 12G. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA 
with Duncan’s post hoc analysis. D0, day 0; D5, day 5, etc.
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ated tumors (35). Finally, histological examination revealed well- 
demarcated AFP+ hepatocellular adenomas in Atg7ΔHep livers (Sup-
plemental Figure 10). There were significantly fewer tumor foci 
in Atg7ΔHep Hmgb1ΔHep livers, even at the age of 12 months. Expan-
sion of tumor foci in Atg7ΔHep livers was evident with reticulin stain-
ing. Interestingly, DCs and fibrotic responses were only present 
outside the tumor foci. Taken together, tumor development in 
autophagy-deficient livers was greatly affected by the events 
resulting from HMGB1-RAGE interaction.
While the data suggested that the HMGB1/RAGE axis might 
affect tumor progression, we also examined some of the molec-
ular events that have been associated with the early tumorigenic 
process. Hedgehog signaling has been implicated in DR and can-
cer development. In Mdr2-deficient livers, which had developed 
strong DR and tumors (36), Hedgehog signaling was elevated, 
and its suppression inhibited DR and tumorigenesis (37). In 
and B). However, we observed tumors in these mice at 12 month 
of age, but in significantly reduced numbers. We combined the 
few mice that had survived to the ages of 15 and 17 months and 
found that the average number of tumors in Atg7ΔHep Hmgb1ΔHep 
mice was only slightly lower than that in Atg7ΔHep mice (Figure 
5B). However, when the size of the tumors was controlled, there 
were fewer tumors in each of the 3 given size groups in Atg7ΔHep 
Hmgb1ΔHep mice than there were in Atg7ΔHep mice (Figure 5C). As in 
the case of DR, we found that deletion of Rage also inhibited tumor 
development in Atg7ΔHep livers. We observed a significant reduc-
tion in tumor numbers and size in Atg7ΔHep Rage–/– livers (Figure 5, 
D and E). In addition, expression levels of the 3 oncofetal genes 
Afp, insulin-like growth factor 2 (Igf2), and reduced in expression 
3 (Rex3) were significantly upregulated in Atg7ΔHep livers, but not 
in Atg7ΔHep Hmgb1ΔHep or Atg7ΔHep Rage–/– livers (Figure 5F). Expres-
sion of these genes represented the development of dedifferenti-
Figure 7. NRF2 is required for hepatic HMGB1 release and DR. (A) Liver sections of 9-week-old mice were H&E stained (original magnification, ×200) or 
stained for HMGB1. (B) Percentage of cells with nuclear HMGB1, serum levels of HMGB1, and number of CK19+ or SOX9+ cells (n = 3–9 mice/group). See 
Supplemental Figure 14D for images of CK19+ and SOX9+ staining. (C) WT mice were given the vehicle control or BM for different durations, and blood 
ALT levels were measured (n = 3–6 mice/group). Variations in ALT values for the control mice (50 days vs. 6 days and 30 days) were due to reagent 
lot changes. (D) WT mice were given the vehicle control or BM for different durations. Hepatic lysates were analyzed by immunoblot assay. (E) Liver 
sections of mice treated with BM or control for 6 days were stained as indicated. Arrows indicate hepatocytes without nucleus HMGB1. (F) Serum levels 
of HMGB1 (n = 3–9 mice/group). (G) Liver sections from mice receiving the 50-day treatment regime were H&E stained (original magnification, ×200) or 
immunostained for CK19. (H and I) Liver sections from mice of the indicated genotypes were H&E stained (original magnification, ×200) or immunos-
tained for HMGB1 or CK19 (H). Yellow arrows indicate hepatocytes without nuclear HMGB1; white arrows indicate hepatocytes with cytosolic HMGB1. (I) 
Cells with nuclear HMGB1 were quantified (n = 3 mice/group). Scale bars: 10 μm (A and E) and 50 μm (G and H). Data represent the mean ± SEM.  
*P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA (B) or Student’s t test (C, F, and I). 
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11D). However, codeletion of Hmgb1 did not correct these chang-
es, implying that HMGB1-mediated tumor progression did not 
involve the alterations of metabolic programming in this context.
HMGB1 is released soon after autophagy function declines. To 
understand how autophagy deficiency led to HMGB1 release, we 
evaluated the temporal relationship of Atg7 deletion and HMGB1 
release. We generated an inducible model of Atg7 deletion in the 
liver by crossing Atg7fl/fl mice with Alb-Cre-ERT2 mice (41). The 
induction of Alb-Cre-ERT2 activity was carried out in adult mice, 
which resulted in loss of autophagy function in hepatocytes, but 
not in cholangiocytes.
The expression of ATG7 in the liver was largely absent 7 days 
after tamoxifen treatment of the inducible strain of mice (Figure 
6A). We found that p62 and NQO1 levels were increased, indicat-
ing a loss of autophagy function and activation of NRF2. HMGB1 
levels started to decline by day 5, and by day 12, immunoblot 
analysis revealed that HMGB1 was at approximately 6% of nor-
mal levels (Figure 6, A and B). We confirmed the loss of HMGB1 
in hepatocytes by immunostaining (Figure 6C). Concomitantly, 
serum HMGB1 levels were progressively increased from day 5 
(Figure 6D), which was in negative correlation with the hepatic 
levels of HMGB1. Early treatment of Atg7Hep-ERT2 mice with EP was 
able to inhibit HMGB1 release (Supplemental Figure 12, A and B). 
Notably, hepatomegaly and liver injury started on days 7 and 15, 
respectively, following Atg7 deletion in Atg7Hep-ERT2 mice (Figure 
6E). Thus, HMGB1 release was sensitive to the loss of autophagy 
function in hepatocytes (days 5–7) and was an early event in paral-
lel with NRF2 activation (days 5–12), but earlier than the appear-
ance of apparent liver injury.
DR was detected by day 30 and progressed subsequently 
(Figure 6F). The expansion of the CK-19+ and A6+ DCs/HPCs 
was evident (Figure 6, G and H, and Supplemental Figure 12, 
C and D) and depended on HMGB1. Codeletion of Hmgb1 in 
Atg7Hep-ERT2 mice did not affect liver injury (Figure 6E), but did 
significantly reduce DR or the expansion of DCs/HPCs (Figure 
6I and Supplemental Figure 12E). We observed hepatic tumors 
in Atg7Hep-ERT2 mice 12 months after tamoxifen induction (Supple-
mental Figure 12, F and G), indicating that autophagy deficiency 
in hepatocytes was sufficient to drive the tumorigenesis. Thus, 
the kinetics link the early release of HMGB1 to the later develop-
ment of DR and tumorigenesis.
Active release of hepatic HMGB1 requires NRF2 in autophagy-de-
ficient livers. The above kinetics data also suggested that HMGB1 
in autophagy-deficient mice might not be due to cellular death. In 
addition, there was very low caspase activity and no release of heat 
shock proteins, which are DAMP molecules commonly released 
from dead cells (Supplemental Figure 13, A and B). Furthermore, 
we detected proliferation signals (PCNA) in hepatocytes that had 
released HMGB1 (Supplemental Figure 13C), indicating their via-
bility. Since HMGB1 can be actively released from viable mono-
cytes and macrophages (11–13), we first examined whether NRF2 
could be involved in the active release of HMGB1 from hepato-
cytes, given its important roles in the autophagy deficiency–related 
liver phenotype (18, 19). Indeed, we found that codeletion of Nrf2 
in Atg7ΔHep or Atg5ΔHep mice prevented the nuclear loss of HMGB1 in 
autophagy-deficient hepatocytes and returned serum HMGB1 to 
normal levels (Figure 7, A and B, and Supplemental Figure 14, A–C).
Atg7ΔHep livers, we found that expression of SHH, a ligand of the 
Hedgehog signaling pathway, was elevated (Figure 5G), while 
Hhip, coding for the inhibitory binding protein of SHH, was 
downregulated (Figure 5H). HHIP downregulation is frequently 
seen in chronic liver injury, where Hedgehog signaling is elevated 
(38). mRNA expression levels of the SHH receptor patched 1 were 
moderately reduced, while mRNA levels of the activator Smo 
were moderately elevated (Figure 5H). Since patched 1 works by 
inhibiting SMO, which is reversed by SHH binding, the detected 
changes in the expression of these genes favored the activation 
of SMO-mediated downstream events. Indeed, we found that 
2 of the downstream effectors, Gli1 at the transcriptional level 
(Figure 5H) and GLI2 at the protein level (Figure 5, G and I), 
were elevated. We detected GLI2 at a molecular weight of 130 
kDa, as previously reported in the liver (39). These changes were 
detected in mice at 9 weeks of age, before tumor development, 
and most of these changes remained detectable by 9 months of 
age, when tumors started to appear. These data suggest that the 
Hedgehog pathway was activated in autophagy-deficient livers 
at the early stage. However, codeletion of Hmgb1 or Rage did not 
significantly reverse these changes, suggesting that the HMGB1/
RAGE axis might work in parallel with, but not contribute to, 
Hedgehog signaling events.
Autophagy deficiency–induced liver tumorigenesis was 
dependent on NRF2 signaling (Figure 5A) (40). In human HCV–
related hepatic cancers, NRF2-dependent tumorigenesis was 
found to be critically related to metabolic reprogramming in 
glutamate metabolism, the pentose phosphate pathway, purine 
nucleotide synthesis, and glucuronate metabolism (40). In Atg7- 
deficient livers, we detected similar changes in the expression 
of key genes involved in these pathways (Supplemental Figure 
11, A and B). These changes included an upregulation of Slc1a1 
(a glutamate transporter) and Gclc (the catalytic subunit of 
glutamate-cysteine ligase), a key enzyme in glutathione synthesis, 
and a reduction of malic enzyme 1 (Me1), an enzyme important for 
the conversion of malate to pyruvate (Supplemental Figure 11C). 
In addition, we detected the upregulation of multiple genes in the 
pentose phosphate pathway as well as those for purine nucleo-
tide synthesis and glucuronate metabolism (Supplemental Figure 
Figure 8. The inflammasome is involved in HMGB1 release in autopha-
gy-deficient liver. (A) Liver lysates from 9-week-old mice were analyzed 
by immunoblotting. (B) Liver sections were stained for HMGB1. Arrows 
indicate hepatocytes without nuclear HMGB1. Scale bars: 10 μm. (C) Cells 
with nuclear HMGB1 were quantified (n = 3 mice/group). (D) Serum levels 
of HMGB1 were measured. (E and F) LW/BW ratios (E) and serum ALT 
levels (F) were measured for 9-week-old mice. (G) Liver sections from 
9-week-old mice were H&E stained. Original magnification, ×200. (H) 
CK19+ and SOX9+ cells were quantified. See also the images in Supple-
mental Figure 19A. (I and J) Hepatic mRNA levels of Casp1 (I) and Casp11 
(J). Primer set 1 located in exon 6 was used for Casp11 amplification. (K–M) 
Liver lysates from 9-week-old mice were analyzed by immunoblotting 
or caspase activity assay (L and M). FL, full length. (N) Model of the role 
of NRF2, inflammasomes, and HMGB1 in liver injury, DR, and tumor 
development. NRF2 activation is required and sufficient for caspase-1 and 
caspase-11 activation and HMGB1 release in autophagy-deficient livers 
and is required, but may not be a sufficient condition, for autophagic liver 
injury or DR. Data represent the mean ± SEM. n = 3–7 mice/group.  
*P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA.
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16G). This was surprising, because, given our study of Atg7Hep-ERT2 
mice (Figure 6, F–H), a period of 30 days after inducing Atg7 dele-
tion (i.e., NRF2 activation) would be sufficient for DR to devel-
op. Taking into consideration that BM stimulation might not be 
equivalent to the genetic activation of NRF2, as in the autophagy- 
deficient livers, we used a mouse strain (caNrf2) that express-
es constitutively activated NRF2 in the liver under control of the 
Alb-Cre promoter (43). Constitutive activation of NRF2 was made 
possible through deletion of the Neh2 domain of NRF2, disabling 
its interaction with KEAP1 (43). These mice developed normally, 
without liver injury (43). We found that the caNrf2 liver histology 
was normal, with no apparent DR or DC/HPC expansion, and 
yet no nuclear HMGB1 (Figure 7, H and I). Taken together, these 
results suggest that NRF2 activation and HMGB1 release alone 
were not sufficient for DR to occur.
We next determined whether NRF2 activation plus a common 
hepatic insult could cause DR. We found that the combination of 
a 30-day BM treatment following administration of a commonly 
used hepatic carcinogen, diethylnitrosamine (DEN), given at the 
adult (Supplemental Figure 17, A–D) or neonatal (Supplemental 
Figure 17, E–G) stage, did not yield DR. Likewise, treatment of 
caNrf2 mice with CCl4 every 3 days for 45 days also did not lead 
to DR, despite a notable fibrotic response (Supplemental Figure 
18A). In both cases, HMGB1 was released (Supplemental Figure 
17, B, C, and F, and Supplemental Figure 18B). Interestingly, CCl4 
alone was able to trigger a noticeable level of HMGB1 release 
(Supplemental Figure 18B), which may be due to the ability of 
CCl4 to activate NRF2 (44). In all cases, the liver injury was mod-
est, with an alanine aminotransferase (ALT) level below 70 IU/l 
(Supplemental Figure 17, D and G, and ref. 43). Thus, minor injury, 
together with NRF2 activation, was not able to drive DR, despite 
the release of HMGB1.
Active release of HMGB1 in autophagy-deficient livers requires 
the participation of inflammasomes. Monocytes and macrophages 
can actively secrete HMGB1 via inflammasome-mediated mech-
anisms (12, 13). The common effector molecule of the inflam-
masome is caspase-1, which is required for the release of HMGB1, 
IL-1β, and IL-18 (11–13). We found that codeletion of Casp1 in the 
Atg7ΔHep liver suppressed nuclear HMGB1 loss without affecting 
p62 accumulation or NRF2 activation (Figure 8A). Hepatocyte 
nuclear HMGB1 was retained, and serum HMGB1 remained at 
the basal level in Atg7ΔHep Casp1–/– mice (Figure 8, B–D). Notably, 
codeletion of Casp1 did not affect hepatomegaly or liver injury 
(Figure 8, E and F), indicating the presence of injury-indepen-
dent mechanisms of HMGB1 release. Consistent with the impor-
tance of caspase-1 in this model, the NRF2 activator BM could not 
induce HMGB1 release in Casp1–/– mice either (Figure 7, E and F).
Functionally, codeletion of Casp1 caused a dramatic reduction in 
DR (Figure 8G) and in the expansion of CK-19+ or SOX9+ DCs/HPCs 
in autophagy-deficient livers (Figure 8H and Supplemental Figure 
19A), without a significant impact on inflammation or fibrosis (Sup-
plemental Figure 19, B and C). Our findings in Atg7ΔHep Casp1–/– mice 
were consistent with those from our studies of Atg7ΔHep Nrf2–/– and 
Atg7ΔHep Hmgb1–/– mice and suggest that the inflammasome was acti-
vated by NRF2, which in turn caused HMGB1 release and DR but not 
other pathologies. Indeed, we found that expression of Casp1 (Figure 
8I), but not of Il1b or Il18 (Supplemental Figure 20, A and B), was ele-
Correspondingly, codeletion of Nrf2 in Atg7ΔHep or Atg5ΔHep 
mice completely suppressed DR and the expansion of DCs/HPCs 
(Figure 7, A and B, and Supplemental Figure 14, D and E). Further-
more, codeletion of Nrf2 in Atg7ΔHep mice inhibited tumor develop-
ment completely (Figure 5A), as reported previously (18, 20, 21). 
Since both DR and tumorigenesis were also affected by HMGB1, 
NRF2 probably regulated these events through the control of 
HMGB1 release.
The DDC diet also caused NRF2 activation (Supplemental 
Figure 15A) and slightly elevated LC3-II levels, the latter of which 
could be due to autophagy inhibition, as cotreatment of chloroquine 
did not further elevate LC3-II levels (Supplemental Figure 15, A 
and B). Consistently, we detected increased levels of high-molec-
ular-weight aggregated p62 (Supplemental Figure 15, A–C), which 
might have been responsible for the elevated NRF2 activation (19) 
in addition to other potential mechanisms. Notably, NRF2 dele-
tion did not completely inhibit HMGB1 release in DDC-treated 
mouse livers (Supplemental Figure 15, D–F). The results thus sug-
gested that the DDC diet could cause NRF2-independent release 
of HMGB1. Consistently, we found that DDC-induced DR was not 
inhibited in Nrf2-deficient livers (Supplemental Figure 15, G and H).
NRF2 activation alone is sufficient to cause HMGB1 release but 
insufficient for DR. We next asked whether NRF2 activation alone 
was sufficient to cause HMGB1 release and DR, without causing 
liver injury and/or autophagy deficiency. Bardoxolone methyl (BM), 
also known as CDDO-Me or RTA 402, is a potent synthetic triter-
penoid derivative that binds to KEAP1 and disrupts its interaction 
with NRF2, causingNRF2 nuclear translocation and activation (42).
We performed studies using several BM treatment regimes 
(Supplemental Figure 16A). In general, treatment with BM for 
up to 50 days had a minor effect on liver weights (Supplemental 
Figure 16B) but did not cause liver injury (Figure 7C). System-
ic administration of BM for 4 or 6 days was sufficient to induce 
NRF2 activation in the liver and in other tissues (Figure 7D and 
Supplemental Figure 16, C–E). HMGB1, but not p62, was signifi-
cantly reduced in the livers of BM-treated WT mice (Figure 7, D 
and E, and Supplemental Figure 16C), but not in the livers of BM- 
treated Nrf2–/– mice (Figure 7E). Concomitantly, we found that 
serum levels of HMGB1 were elevated in BM-treated WT mice, 
but not in BM-treated Nrf2–/– mice (Figure 7F). We also observed 
this close relationship of HMGB1 release and NRF2 activity with 
the different treatment regimes (Supplemental Figure 16C). NRF2 
activation subsided and HMBG1 levels rebounded after a 6-day 
BM treatment that was followed by a 16-day rest without BM 
treatment (22-day regime). But if BM treatment was continued 
after the first 6 daily treatments (6-day plus 14-day regime), we 
observed sustained NRF2 activation along with HMGB1 release. 
Hepatocytes were much more sensitive to BM treatment in terms 
of HMGB1 release, whereas other tissues did not have significant 
HMGB1 release with the 6-day regime (Supplemental Figure 16, E 
and F). These findings indicated that systemic NRF2 activation by 
a pharmacological agent could induce NRF2-dependent HMGB1 
release without causing tissue injury or autophagy deficiency, indi-
cating active secretion of HMGB1 from the affected hepatocytes.
Surprisingly, BM-treated livers did not develop DR or expan-
sion of CK19+ DCs despite the release of HMGB1, even in the 
long-term 50-day treatment (Figure 7G and Supplemental Figure 
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phages are able to actively secrete HMGB1 (11–13). We report here 
that hepatocytes can release HMGB1 actively and independently 
of cell death. Several lines of evidence support this: (a) Acetylated 
forms of HMGB1 can be found in the blood of autophagy- 
deficient mice; (b) Atg7Hep-ERT2 mice release HMGB1 almost imme-
diately after Atg7 deletion, before the development of liver injury; 
(c) hepatocytes releasing HMGB1 can also express proliferation 
markers such as PCNA; (d) HMGB1 release from hepatocytes 
depends on NRF2 and can be induced by BM, an NRF2 activa-
tor, or induced in caNrf2 mice in which NRF2 is constitutively 
activated; both conditions do not cause liver injury; and (e) disrup-
tion of the Casp1-engaged inflammasomes blocks HMGB1 release 
but does not affect liver injury.
Several forms of posttranslational modifications, such as phos-
phorylation, methylation, and acetylation can result in accumula-
tion of HMGB1 in the cytosol (50). HMGB1 modification occurs in 
immune cells (50) and is implicated in the translocation of HMGB1 
in hepatocytes from ethanol-fed mice (16). Acetylation was shown 
to be required for HMGB1 to be shuttled out of the nucleus to the 
cytosol before its release into the extracellular space (17), thus rep-
resenting an active process. On the other hand, HMGB1 passively 
released from dead cells is not acetylated (8). We found acetylated 
HMGB1 in the blood of autophagy-deficient mice but not in 
blood from control mice (Figure 1G). Therefore, HMGB1 acetyl-
ation stimulated by autophagy deficiency constitutes a key step 
in the active release of HMGB1. With the codeletion of Nrf2, 
nucleus-cytosol translocation of HMGB1 and release of HMGB1 
were inhibited in autophagy-deficient hepatocytes. NRF2 activa-
tion in autophagy-deficient hepatocytes is well documented (19), 
but how NRF2 may promote HMGB1 translocation is not known. 
We speculate that NRF2 may affect the posttranslational modifica-
tion of HMGB1, including acetylation, or that NRF2 activation may 
alter the nuclear structure to affect HMGB1 binding to DNA.
Active secretion of HMGB1 by macrophages or monocytes is pro-
posed to be mediated by a nonclassical mechanism (11), as HMGB1 
does not contain a secretion leader sequence. Inflammasomes 
may be critically involved (12, 13). In activated macrophages, dsR-
NA-dependent protein kinase (PKR) is important for triggering 
inflammasome/caspase-1–mediated secretion of HMGB1 (13). Our 
studies indicated that the active release of HMGB1 from hepato-
cytes can also involve the inflammasome component caspase-1. 
In macrophages, caspase-1 can be activated by the canonical path-
ways involving several different inflammasome components but 
can also be activated by caspase-11 via a noncanonical pathway 
(47–49). Upregulated expression of caspase-11 appeared to be 
essential for this pathway, which was stimulated by LPS. Caspase-11 
and caspase-1 were significantly upregulated in the autophagy- 
deficient livers in a NRF2-dependent manner. Further studies are 
needed to determine whether NRF2, perhaps together with other 
factors, transcriptionally affects the expression of these caspases in 
autophagy-deficient livers.
Caspase-1 and caspase-11 can cleave gasdermin D to form 
transmembrane pores to release IL-1β from macrophages (45, 
46). Active HMGB1 release has been known to correlate with the 
release of IL-1β (12, 13) and can thus be dependent on gasder-
min D–formed pores. We detected increased proteolytic activity 
against gasdermin D in autophagy-deficient livers in a NRF2- 
vated in autophagy-deficient livers in a NRF2-dependent manner, 
supporting the above hypothesis and implying a more specific role of 
caspase-1 in HMGB1 release but not in IL-1β nor IL-18 release in the 
autophagy-deficient setting.
Interestingly, we found that expression levels of Casp11 (Fig-
ure 8J and Supplemental Figure 20C), but not of Casp2, Casp3, 
or Casp9 (Supplemental Figure 20, D–F), were also elevated in 
Atg7ΔHep livers in an NRF2-dependent manner. Both caspase-1 
and caspase-11 were activated, as indicated by the appearance of 
the activated subunits in Atg7ΔHep livers, but not in Atg7ΔHep Nrf2–/– 
livers (Figure 8K and Supplemental Figure 21A). Cytosolic YVA-
Dase activity (mainly caspase-1 activity) (Figure 8L and Supple-
mental Figure 21B) and LLSDase activity (mainly caspase-11 and 
caspase-1 activity) (Figure 8M) levels were elevated in Atg7ΔHep 
livers and were abolished by codeletion of Nrf2 or Casp1, but not 
by codeletion of Hmgb1, in the autophagy-deficient livers. The 
LLSD sequence was derived from murine gasdermin D, a recently 
identified substrate of caspase-1 and caspase-11 (45, 46).
The coexistence of caspase-1 and caspase-11 activation in 
autophagy-deficient livers in our study was notable, since previous 
studies showed that caspase-1 could be activated noncanonically 
in macrophages by caspase-11, which triggered IL-1β release via 
caspase-1/-11 cleavage of gasdermin D, forming transmembrane 
pores composed of cleaved N-terminal gasdermin D fragments 
(47–49). Consistent with the elevated LLSDase activity, cleaved 
gasdermin D fragment levels were increased in Atg7ΔHep livers in a 
NRF2-dependent manner (Figure 8K). On the other hand, expres-
sion of gasdermin D and other related gasdermin family proteins 
was not elevated in these livers (Supplemental Figure 20G). These 
data support a model in which NRF2 activates the caspase-11 and 
caspase-1 inflammasome to promote gasdermin D cleavage and 
gasdermin D pore formation, leading to HMGB1 release from 
autophagy-deficient hepatocytes (Figure 8N).
In contrast to the autophagy deficiency, deletion of Casp1 only 
resulted in an incomplete reduction of HMGB1 release (Supple-
mental Figure 22, A–C) and did not inhibit DR (Supplemental Fig-
ure 22, D and E) in the DDC diet model. Elevation of YVADase or 
LLSDase activity was not evident (Supplemental Figure 22, F and 
G). The presence of an inflammasome-independent mechanism 
for DDC diet–triggered HMGB1 release and subsequent DR was 
consistent with the presence of the NRF2-independent mecha-
nisms described above (Supplemental Figure 15). It is possible that 
this mechanism was related to cell breakdown, as both cytoso-
lic HSP90 and HSP70 levels were reduced in DDC-treated livers 
(Supplemental Figure 22H) and were not affected in autophagy- 
deficient livers (Supplemental Figure 13B). We detected no reduc-
tion in TUNEL levels in Casp1–/– or Nrf2–/– livers following DDC diet 
treatment (Supplemental Figure 22I) but found that serum ALT 
levels were elevated (Supplemental Figure 22J). These results sug-
gest that, while HMGB1 was still important for DDC diet–induced 
DR, HMGB1 release could also be due to NRF2/inflammasome- 
independent mechanisms, such as cellular breakdown.
Discussion
Loss of autophagy function triggers active HMGB1 release from 
hepatocytes. HMGB1 is usually released from disintegrated dead 
cells in a passive process (8). However, monocytes and macro-
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HMGB1 acts as an extrinsic mechanism for DC/HPC expan-
sion and requires its receptor RAGE. RAGE is expressed on a vari-
ety of cell types that have been shown to participate in HMGB1- 
mediated effects (57, 58). HMGB1 interaction with RAGE can 
mediate cell proliferation, growth, and migration by activating 
intracellular signals such as NF-κB and the MAPK pathway (57, 
58). We found that autophagy deficiency–induced DCs/HPCs 
expressed RAGE and CK19 and responded to dsHMGB1 with 
increased ERK signaling. Similar observations have been made in 
Mdr2-deficient livers and in mice fed a CDE diet. In both cases, 
DR was also dependent on RAGE (36). Thus, it may be assumed 
that, unlike the case in which HMGB1 interacts with TLRs (TLR2, 
TLR4, etc.) on inflammatory/fibrotic cells to drive inflamma-
tion and fibrosis, HMGB1 interacts with RAGE on DCs/HPCs in 
autophagy-deficient livers to drive the DR that may represent the 
repair process (6, 54).
It is important to note that our studies also indicate that HMGB1 
may not work alone to promote DC/HPC expansion, because acti-
vation of NRF2 alone can cause HMGB1 release but not DR. NRF2 
activation and/or HMGB1 may be necessary but insufficient for 
DR in autophagy-deficient livers (Figure 8N). There are probably 
other signals that facilitate the expansion of DCs/HPCs. Factors 
such as TWEAK and FGF7 (55, 56) and events such as Hedgehog 
signaling (38, 39) may be concomitantly needed. Another key 
factor may be liver injury stimulation, which occurs in autophagy- 
deficient livers and may trigger the above-mentioned mechanisms 
(22, 23). The simple combination of NRF2 activation (chemical or 
genetic) and common liver insults (DEN or CCl4) did not result in 
DR, possibly because such combinations may not cause the nec-
essary signaling events. Future work should be directed at defin-
ing the other conditions under which DR occurs in the autophagy 
deficiency setting.
Toxic diets, such as those containing DDC or CDE, are well 
known for their ability to cause liver injury and DR (25, 26). This 
study shows that the HMGB1/RAGE axis is also an important 
mechanism for inducing DR following treatment with a DDC or 
CDE diet but that HMGB1 release may not be entirely controlled 
by the NRF2/inflammasome pathway in this setting. Although a 
DDC diet caused some autophagy deficiency and NRF2 activa-
tion, the latter was not potent enough, or needed additional cofac-
tors not available with DDC treatment, to activate caspase-1 and 
caspase-11. In addition, we found that deletion the Nrf2 or Casp1 
gene was unable to completely block HMGB1 release and DR, sug-
gesting the presence of cellular breakdown. We observed a con-
comitant loss of other intracellular DMAP molecules in WT mice 
fed a DDC diet. Together, these data suggest a dominant presence 
of passive HMGB1 release as a result of cellular breakdown. Nev-
ertheless, despite the difference in the way in which HMGB1 is 
released, HMGB1 is as important for DR in toxic diet treatments 
as it is in autophagy deficiency.
Controlling HMGB1 dynamics can be an important mechanism 
in autophagy-mediated suppression of tumor development. Autoph-
agy is an important mechanism regulating tumorigenesis (2, 59). 
Although autophagy provides a prosurvival anti-stress and nutri-
ent-sustaining mechanism in cancer cells, it serves to suppress 
tumorigenesis in normal cells. There may be multiple mecha-
nisms  — such as removing damaged mitochondria and controlling 
dependent manner. Overall, these data support a working mod-
el, in which NRF2 activation causes upregulation and activation 
of caspase-1 and caspase-11, which leads to cleavage of gasdermin 
D and the formation of gasdermin D pores for HMGB1 release 
from hepatocytes. This hypothesis has yet to be fully examined 
using additional genetic models to assess the independent role of 
caspase-11 and gasdermin D.
It should be pointed out that NRF2-promoted HMGB1 release 
may work in a cell-dependent fashion. Mechanisms acting in one 
type of cell may not be fully accountable for HMGB1 dynamics in 
another cellular system. Hepatocytes can be particularly suscepti-
ble to the NRF2/inflammasome pathway for HMGB1 release.
HMGB1-mediated DR may represent a repair and regeneration 
response to liver injury. DR has been observed in many different 
liver injury conditions with diverse etiologies (22, 23) and has 
also been viewed as a process of liver repair and regeneration in 
response to chronic liver injury (24), which can also be patho-
genically associated with fibrosis (23). DR reflects the expan-
sion of DCs/HPCs from the portal region to the parenchyma. 
The origin and nature of these cells are still controversial, 
despite the fact that they usually carry biliary epithelial mark-
ers. DCs/HPCs have been implicated in compensatory epitheli-
al hyperplasia and in the regeneration of hepatocytes or cholan-
giocytes that are important for hepatic regeneration and repair 
(24, 51, 52), although this may not always be demonstrated 
in every model system (53).
As a key DAMP molecule, extracellular HMGB1 is often 
associated with injury, inflammation, fibrosis, and notably repair 
(5–7, 10, 15, 16). However, in liver injury caused by autophagy defi-
ciency, hepatocyte-derived HMGB1 was dispensable for sterile 
inflammation or fibrosis, but was required for DR. Inflammation 
and fibrosis were both still present in the absence of HMGB1 in 
autophagy-deficient livers, which, however, may not necessarily 
indicate that HMGB1 was not involved in the process, but suggests 
that there could be multiple redundant mechanisms. Thus, the 
impact of HMGB1 on DC/HPC expansion may be mostly related 
to their roles in tissue repair (6, 51, 52) and not in inflammation or 
fibrosis. Consistent with this thought, HMGB1 was also found to 
be important for regeneration but not inflammation in a model of 
spinal cord injury (54).
Understanding the signaling pathways that are involved 
in DC/HPC activation, proliferation, and differentiation is 
important for gaining insight into the biology of DCs/HPCs 
and their role in liver pathology and regeneration. Howev-
er, little is known about the signals that drive DR or that pro-
mote DC/HPC expansion. TNF-like weak inducer of apoptosis 
(TWEAK) and FGF7 have been shown to induce mitogenesis in 
DCs/HPCs and to be involved in DR in injured livers (55, 56). 
However, the long-term effects of these factors were not clear. 
Hedgehog signaling has also been implicated in DR (38, 39). 
We found that HMGB1 was required for DC/HPC expansion 
in autophagy deficiency and had a long-term impact. We did 
not detect DR in Atg7 Hmgb1ΔHep mice, even at 9 months of age. 
Furthermore, we detected an increase in Hedgehog signaling in 
autophagy-deficient livers. Thus, HMGB1 may be complemen-
tary to Hedgehog signaling or to TWEAK/FGF7 in activating 
DR in autophagy-deficient livers.
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The Jackson Laboratory. The liver-specific inducible Atg7-deficient 
mice (Atg7Hep-ERT2) were generated by crossing Atg7fl/fl mice with Alb- 
Cre-ERT2 mice (41). Deletion of Atg7 was induced by s.c. administra-
tion of tamoxifen (6 mg/day, ×2 days). Strains with multiple gene 
alterations were created by crossbreeding. Mice were maintained on 
a 12-hour light/12-hour dark cycle with free access to food and water. 
A mixture of male and female mice were used at the ages indicated in 
the figure legends.
Antibodies and chemicals. The antibodies used in this study are list-
ed in Supplemental Table 1. Tamoxifen (Sigma-Aldrich) was diluted 
in corn oil. Bardoxolone methyl (Cayman Chemical) was dissolved in 
DMSO, diluted in corn oil, and administrated i.p. (10 mg/kg). EP (Acros 
Organics, Thermo Fisher Scientific) was administered i.p. (40 mg/kg) 
twice a week for 2 or 4 weeks. The control mice received the vehicles.
Cell preparation and culture. Primary hepatocytes and nonparen-
chymal cells were isolated from mice using a collagenase-based stan-
dard reverse perfusion procedure. Hepatocyte purity exceeded 95% as 
assessed by light microscopy, and viability was typically greater than 
80% as determined by a trypan blue exclusion assay. Nonparenchy-
mal cells were fractionated using a multilayer discontinuous Nyco-
denz density gradient (11%, 13%, 15%, 19%, and 26%) as previously 
described (25). F1, F2, F3, and F4 cells were isolated from the interface 
between 11% and 13%, 13% and 15%, 15% and 19%, and 19% and 26%, 
respectively, after centrifugation at 1,500 g for 1 hour. These cells were 
then cultured overnight in William’s E medium supplemented with 
10%FBS, EGF (10 ng/ml), insulin (10 μg/ml), glutamine (200 mM), 
and a penicillin-streptomycin combination before they were washed 
and subjected to experimental conditions. The progenitor cell line 
BMOL was obtained from G.C. Yeoh (The University of Western Aus-
tralia, Crawley, Australia) (29), and cultured in the same medium as 
the primary cells.
Biochemical analysis. Serum levels of ALT, aspartate aminotrans-
ferase (AST), and alkaline phosphatase (ALP) were measured using 
commercially available kits from Pointe Scientific according to the 
manufacturer’s protocol. Serum levels of HMGB1 were analyzed using 
an ELISA kit (Aviva Systems Biology) according to the manufacturer’s 
instructions. Mass spectrometric analysis of serum HMGB1 was con-
ducted as previously described (16). Measurement of 4-hydroxypro-
line in liver tissues was performed using a hydroxyproline colorimetric 
assay kit (Biovision) according to the manufacturer’s instruction.
Caspase assay. Caspase activity was assessed by the cleavage of 
site-specific reporter substrates. Total liver lysate equivalent to 20 to 
40 μg protein were incubated at 37°C with 20 to 50 μM peptide sub-
strates in caspase assay buffer (20 mM PIPES, pH 7.2, 100 mM NaCl, 1 
mM EDTA, 0.1% CHAPS, 10% sucrose, 2 mM DTT) for 1 to 16 hours. 
Ac-DEVD-AFC, Ac-IETD-AFC, Ac-LEHD-AFC, Ac-LLSD-AFC, and 
Ac-YVAD-AFC were the fluorogenic substrates used for the caspase-3, 
caspase 8, caspase-9, caspase-11, and caspase-1 activity assays, respec-
tively. Cleavage by caspases was detected at the excitation/emission 
wavelength of 400 nm/505 nm by a fluorescence spectrometer (Tec-
an Infinite M200 Pro). Fluorescence readings were normalized to the 
background and standardized to the amount of protein analyzed.
RNA isolation and quantitative real-time PCR analysis. Total RNA 
was extracted from liver samples using a GeneTET RNA Purifica-
tion Kit (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. cDNA was synthesized from 1 μg total RNA using a M-MLV 
Reverse Transcriptase Enzyme System (Life Technologies, Thermo 
oxidative stress — by which autophagy can achieve this tumor- 
suppressing effect. Deletion of autophagy genes in the liver leads 
to the development of adenoma, for which NRF2 is a critical initia-
tor (18, 20, 21). Accumulation of p62 in autophagy-deficient livers 
drives NRF2 activation, which can lead to metabolic reprogram-
ming and mTORC1 activation and thereby contribute to tumor 
initiation (20, 40, 60).
The present study suggests that controlling HMGB1 release 
can be another important mechanism in autophagy-mediated 
tumor suppression. Our study suggests that this effect of HMGB1 
was related to the progression, but not initiation, of the tumor, 
since deletion of HMGB1 did not eliminate the tumors, but signifi-
cantly delayed their development or metabolic reprogramming is 
consistent with the notion that HMGB1 is involved in processes 
other than tumor initiation.
The role of HMGB1 in tumor development has been studied 
in different contexts (33, 34). As a key DAMP molecule, HMGB1 is 
commonly associated with tissue injury, inflammation, and fibro-
sis (5, 6), and, given the strong evidence supporting a relationship 
between inflammation and cancer, HMGB1 may be implicated 
in cancer development via these mechanisms (3, 4). However, 
in autophagy-deficient livers, HMGB1 may promote tumor pro-
gression via a mechanism independent of its usual role in injury, 
inflammation, and fibrosis, as we did not observe a significant 
impact of HMGB1 deletion on these processes.
Since both hepatic tumor development and DR are promoted 
by HMGB1 and RAGE in autophagy-deficient livers, the question 
arises whether there are any connections between the 2 events. 
Notably, RAGE is also simultaneously involved in these 2 events in 
Mdr2-deficient livers (36). While DCs/HPCs have been speculated 
to be involved in hepatic tumor development, lineage-tracing 
studies using a number of hepatocellular carcinoma models were 
unable to show that tumor cells could be derived from these cells 
(32). Thus, if HMGB1-mediated DC/HPC expansion is related to 
HMGB1-mediated tumor progression, these 2 processes may be 
indirectly associated. A potential mechanism is that DCs/HPCs 
may affect the tumor microenvironment, e.g., matrix-cell interac-
tion, which is related to hepatic repair and may thus also affect tumor 
development. Alternatively, the 2 HMGB1-regulated processes may 
represent a common growth factor–like effect of HMGB1 on differ-
ent types of cells in the injured liver. These possibilities will need to 
be examined in future studies.
This study reveals the importance of HMGB1 in mediating 2 crit-
ical hepatic pathogenic processes in injured liver under autophagy- 
deficient conditions. Our study provides mechanistic insights into 
DC/HPC expansion and how autophagy may suppress tumor devel-
opment in the liver via the control of HMGB1 release.
Methods
Animals. Alb-Cre:Atg7 mice (19), Alb-Cre:Atg5 mice (21), Alb-Cre:Vps34 
mice (61), PEPCK (phosphoenolpyruvate carboxykinase)-Cre Atg7 mice 
(62), Alb-Cre:hmgb1 mice (63), Rage-deficient mice (64), caNrf2 mice 
(43), and the corresponding floxed control mice have been described 
previously. Alb-Cre:Atg5 mice (Atg5 flox, B6.129S-Atg5tm1Myok) were pur-
chased from the RIKEN BioResource Research Center. Casp1-deficient 
mice (B6N.129S2-Casp1tm1Flv/J, stock no. 016621) and Nrf2-deficient 
mice (B6.129X1-Nfe2l2tm1Ywk/J, stock no. 017009) were purchased from 
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tigroup comparisons). The statistical analysis methods chosen were 
appropriate for distribution fitting and variance. P values of less than 
0.05 were considered statistically significant.
Study approval. All animal experiments were approved by the 
IACUC of Indiana University.
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Fisher Scientific) and OligodT primers. qPCR was performed using 
SYBR Green Master Mixes on a 7500 FAST Real-Time PCR System 
(Life Technologies–Applied Biosystems, Thermo Fisher Scientific). 
Gene expression was calculated using the 2–ΔΔCt method and normal-
ized to the housekeeping gene Actb. Gene-specific primers and their 
sequences are shown in Supplemental Table 2.
Immunoblotting. Immunoblot analysis was conducted as previ-
ously described (18). The images were digitally acquired with a Kodak 
Image Station 4000 (Carestream Health Inc.) or a Bio-Rad ChemiDoc 
Image System with the corresponding software. Densitometric analy-
sis was performed using the companion software, and the values were 
normalized to the loading control (β-actin or GAPDH) and then con-
verted to units relative to the control.
Immunofluorescence microscopy. Paraffin sections were subjected 
to antigen retrieval using citrate buffer (pH 6.0) after deparaffiniza-
tion. Slides were permeabilized and blocked with 5% goat or donkey 
serum in PBS containing 0.1% Triton X (PBS-Tx) and glycine for 1 
hour and then incubated overnight at 4oC with primary antibodies 
diluted in PBS. Sections were washed in PBS-Tx, following by incu-
bation with fluorochrome-conjugated secondary antibodies. Hoechst 
33342 (1 μg/ml) was used for staining of nuclei. Images were obtained 
using a Nikon Eclipse TE 200 epi-immunofluorescence microscope 
and the companion NIS-Elements AR3.2 software.
Histological analysis. Formalin-fixed mouse tissue was processed 
and stained with H&E, Picrosirius red, or trichome or was stained for 
F4/80, CD3, CD45, or MPO for macrophages, T cells, B cells, and 
neutrophils, respectively, at the Indiana University Health Pathology 
Laboratory. Images were obtained using a Nikon Eclipse E200 micro-
scope equipped with a SPOT RT Slider color digital camera (Diagnos-
tic Instruments).
Statistics. Data are presented as the mean ± SEM. The number of 
mice in individual experiments is shown in the figure legends. Statis-
tical analysis was performed using SigmaStat 3.5 (Systat Software). P 
values from at least 3 independent determinations or samples were 
calculated using a 2-tailed Student’s t test (for paired group compari-
sons) or 1-way ANOVA with the appropriate post hoc analysis (for mul-
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